Is haemophilia prophylaxis achievable in the context of self-sufficiency?
In Sweden prophylactic treatment in haemophilia was introduced in 1958. Patients receiving prophylactic treatment have less time off school or work, require less hospitalization, have fewer joint bleeds, and generally lead as near normal life as possible. Although prophylaxis is expensive the cost is off-set by the improvement in quality of life and in productivity. At present, Sweden is almost self-sufficient in blood products for prophylactic treatment of haemophiliacs.
Nilsson
I M
IM
Department for Coagulation Disorders, University of Lund, Malmö General Hospital, Sweden.
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D005164:Factor IX / Q000008:administration & dosage* / Q000191:economics / Q000493:pharmacokinetics / Q000600:supply & distribution; D005169:Factor VIII / Q000008:administration & dosage* / Q000191:economics / Q000493:pharmacokinetics / Q000600:supply & distribution; D005500:Follow-Up Studies; D006467:Hemophilia A / Q000150:complications / Q000191:economics / Q000453:epidemiology / Q000628:therapy*; D002836:Hemophilia B / Q000150:complications / Q000191:economics / Q000453:epidemiology / Q000628:therapy*; D006801:Humans; D007592:Joint Diseases / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D008297:Male; D011788:Quality of Life; D013548:Sweden / Q000453:epidemiology; D016896:Treatment Outcome
D005169:Factor VIII; D005164:Factor IX